GlycoMira is developing synthetic glycosaminoglycan-based therapeutics that modulate the innate immune molecules. Our technology has the potential to address tremendous unmet needs for radiation oncology and chronic respiratory indications. With private investments, Utah state, and federal government grant awards from the National Institutes of Health, GlycoMira has demonstrated safety and efficacy of its lead drug candidate against a broad spectrum of inflammatory diseases.